Verastem Inc VSTM:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 02/26/21 EST
2.36quote price arrow up+0.01 (+0.43%)
Volume
55,974
Close
2.35quote price arrow down-0.01 (-0.42%)
Volume
1,996,897
52 week range
1.08 - 4.67

...

Loading . . .

KEY STATS

  • Open2.38
  • Day High2.48
  • Day Low2.34
  • Prev Close2.36
  • 52 Week High4.67
  • 52 Week High Date04/23/20
  • 52 Week Low1.08
  • 52 Week Low Date09/04/20
  • Market Cap398.96M
  • Shares Out169.77M
  • 10 Day Average Volume4.26M
  • Dividend-
  • Dividend Yield-
  • Beta1.08
  • 1 Year % Change23.04

RATIOS/PROFITABILITY

  • EPS (TTM)-0.92
  • P/E (TTM)-2.55
  • Fwd P/E (NTM)-6.62
  • EBITDA (MRQ)-60.62M
  • ROE (MRQ)-114.53%
  • Revenue (MRQ)91.63M
  • Gross Margin (MRQ)63.69%
  • Net Margin (MRQ)-94.55%
  • Debt To Equity (MRQ)43.57%

EVENTS

  • Earnings Date03/13/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Verastem Inc News

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
Verastem, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing medicines to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The Company’s marketed and developing products include defactinib and VS-6766. Defactinib is an oral small molecule inhibitor of FAK and PYK2 that is being evaluated as a potential combination therapy for various solid tumors. It is...
Brian Stuglik
Chief Executive Officer
Daniel Paterson
President
Robert Gagnon
Chief Financial Officer
Address
117 Kendrick St Ste 500
Needham, MA
02494-2730
United States